Pipeline dossier

NIH & clinical-trial pipeline signals for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for TAK, mapped to public ticker TAK (CIK 0001395064). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingTAK35% conf

TAKEDA PHARMACEUTICAL CO LTD (TAK) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

JSON API for this entity →